Evidence map›Paper›PMID 33095154›Full record

ArticleRegenerative medicine research2020

Siwei Jianbu decoction improves painful paclitaxel-induced peripheral neuropathy in mouse model by modulating the NF-κB and MAPK signaling pathways.

Jinshuai Suo, Man Wang, Peng Zhang, Yuting Lu, Rong Xu, Ling Zhang, Siyan Qiu, Qiuyan Zhang, Yangyan Qian, Jing Meng and 1 more

Open access · goldAbstract read
In one paragraph

Article in Regenerative medicine research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. TRPV4 Role in Neuropathic Pain Mechanisms in Rodents.Antioxidants (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jinshuai SuoJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Man WangJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Peng ZhangJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Yuting LuJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Rong XuJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Ling ZhangJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Siyan QiuJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Qiuyan ZhangJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Yangyan QianJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jing MengJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jing ZhuJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Department of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China - Department of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, USA.
Nanjing University of Chinese Medicine · CNJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPaclitaxel, a commonly used chemotherapeutic agent, is usually associated with peripheral neuropathy. Paclitaxel induced peripheral neuropathy (PIPN) can be dose limiting and may have detrimental influence on patients' quality of life. However, the mechanism of PIPN remains unclear. Medicinal herbs and their formulas might offer neuronal protection with their multitarget and integrated benefits in chemotherapy-induced peripheral neuropathy (CIPN). Siwei Jianbu decoction (J12) is a classic formula of traditional Chinese medicine which can promote blood circulation and treat diabetic nephropathy in clinical with the symptoms of weakness and pain.

methodsThe effects of J12 were treated in C57BL/6 mice before injected with Paclitaxel.Behaviour studies: Measurement of mechanical hyperalgesia, thermal nociception and cold allodynia. On the last day at the end of week 6, DRGs were obtained from mice for western blot and immunohistochemical analysis containing NF-κB, p-ERK1/2 and p-SAPK/JNK protein expression. Quantitative real-time polymerase chain reaction: mRNA expression of NF-κB, IL-1β and TNF-α was analyzed. Additionally, the blood samples collected from the eye socket of the mouse were prepared to examine the levels of NF-κB, TNF-α, IL-6 and IL-1β using ELISA assay kits.

resultsHypersensitivity tests and pathology analysis have demonstrated that J12 could improve paclitaxel-induced peripheral pain. J12 acts by inhibiting the activation of (C-Jun N-terminal kinases) JNK, (extracellular signal-regulated kinase) ERK1/2 phosphorylation in (Mitogen-activated protein kinases) MAPK signaling pathway and the nuclear factor-κB (NF-κB) in C57BL/6 mice model, J12 also inhibits the production of inflammatory cytokines including tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and IL-6.

conclusionThe present study showed that J12 ameliorates paclitaxel-induced peripheral neuropathic pain.

Indexed as

MAPK signaling pathwayNF-κBpaclitaxelperipheral neuropathic painSiwei Jianbu decoction

Identifiers

PMID33095154
PMCPMC7583579
OpenAlexW3093687287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.